A Phase 1 randomized, double-blind, placebo controlled dose escalation clinical trial to evaluate the safety and immunogenicity of recombinant adenovirus serotype 26 HIV-1 vaccine (ad26.ENVA.01) in healthy, HIV-1 uninfected adults.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HIV vaccine Ad26 ENVA-01 (Primary)
Indications HIV-1 infections
Focus Adverse reactions

Most Recent Events

31 Oct 2016 Status changed from active, no longer recruiting to completed.
05 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2010 to 1 Jul 2011.
05 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed to 1 Jul 2011.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight